We provide you with 20 years of free, institutional-grade data for IMAB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IMAB. Explore the full financial landscape of IMAB stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about IMAB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
I-Mab(NASDAQ:IMAB) 
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody th...
Website: https://www.i-mabbiopharma.com/
Founded: 2014
Full Time Employees: 229
CEO: Huaqiong Shen
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends